Dec. 22, 2003 — NanoBio Corp., an Ann Arbor, Mich.-based firm specializing in nanotechnology-based pharmaceuticals, announced it has received a $3.2 million federal contract and is spinning off a company.
null
The U.S. Defense Department contract will be used to continue NanoBio’s development of its antimicrobial nanoemulsions, which incorporate nanoparticles for biodefense and drug delivery applications.
null
The company also has formed a new firm, NanoCure Corp., to commercialize dendrimer-based drug-delivery and imaging platforms. Funded by state and federal grants, NanoCure is preparing to have technology ready for clinical trials within two years, according to a company news release.
null
NanoBio and NanoCure are developing technology licensed from University of Michigan’s Center for Biologic Nanotechnology.